Pemvidutide Shows Promise for Liver Disease and Cardiometabolic Health in Phase 2b Trial
A dual GLP-1/glucagon receptor agonist cuts triglycerides, blood pressure, and liver fibrosis markers over 48 weeks in MASH patients.
Summary
Altimmune's drug pemvidutide, a dual glucagon and GLP-1 receptor agonist, showed meaningful improvements in liver and heart health markers over 48 weeks in people with metabolic dysfunction-associated steatohepatitis, or MASH — a serious liver disease linked to obesity and metabolic syndrome. Results from the IMPACT Phase 2b trial showed reductions in triglycerides, cholesterol, blood pressure, body weight, and waist circumference, plus improvements in liver fibrosis and stiffness. The drug was generally well tolerated, with few dropouts due to side effects. Investment firm Leerink initiated coverage with an Outperform rating, citing pemvidutide's unique dual-agonist profile as a differentiator in a competitive MASH drug market.
Detailed Summary
Metabolic dysfunction-associated steatohepatitis, or MASH, is a progressive liver disease driven by excess fat accumulation, inflammation, and fibrosis — and it remains one of the fastest-growing causes of liver failure globally. Effective treatments are scarce, making new therapeutic candidates a significant focus for both clinicians and investors.
Altimmune's pemvidutide targets two key metabolic receptors simultaneously — GLP-1 and glucagon — creating a dual-agonist effect that may address both liver disease and broader cardiometabolic dysfunction more comprehensively than single-target drugs. Data from the 48-week IMPACT Phase 2b trial, presented at the European Association for the Study of the Liver Congress 2026 in Barcelona, showed that patients on the 1.8 mg dose experienced notable reductions in triglycerides, total cholesterol, systolic and diastolic blood pressure, body weight, BMI, and waist circumference compared to placebo.
Critically for a liver disease drug, earlier trial data also demonstrated improvements in liver fibrosis scores and liver stiffness — structural markers that predict long-term disease progression. These findings suggest pemvidutide may slow the underlying damage driving MASH, not just improve surface-level metabolic numbers.
The drug was generally well tolerated across the 48-week period, with only a small proportion of participants discontinuing due to adverse events — a positive safety signal for a drug intended for long-term use. Leerink's Outperform rating and $10 price target reflect confidence in pemvidutide's differentiated profile and potential expansion into alcohol-related liver disease and other adjacent indications.
Important caveats apply: this is Phase 2b data, meaning larger Phase 3 trials are needed before regulatory approval. The article is a financial coverage report, not a peer-reviewed study, and primary trial publications should be consulted for full statistical details and patient demographics.
Key Findings
- Pemvidutide at 1.8 mg reduced triglycerides, cholesterol, blood pressure, BMI, and waist circumference versus placebo over 48 weeks.
- Earlier IMPACT trial data showed liver fibrosis and liver stiffness improvements, key markers of MASH disease progression.
- The drug's dual GLP-1 and glucagon receptor agonism may offer broader metabolic benefits than single-target therapies.
- Pemvidutide was well tolerated over 48 weeks with few discontinuations due to adverse events.
- Leerink assigned an Outperform rating, highlighting potential expansion into alcohol-related liver disease indications.
Methodology
This is a financial news report summarizing an investment analyst's coverage initiation and Phase 2b clinical trial results. The evidence basis is the IMPACT trial (48-week data), presented at a major liver disease congress. Primary peer-reviewed publication data were not directly cited.
Study Limitations
This article is a financial analyst coverage report, not a peer-reviewed clinical publication, limiting the depth of statistical and safety detail available. Phase 2b results require confirmation in larger Phase 3 trials before clinical conclusions can be drawn. Readers should consult the primary trial publication and ClinicalTrials.gov for full methodology and patient population data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: